Arrhythmogenic Right Ventricular Cardiomyopathy: Progress Toward Personalized Management
- PMID: 30355260
- DOI: 10.1146/annurev-med-041217-010932
Arrhythmogenic Right Ventricular Cardiomyopathy: Progress Toward Personalized Management
Abstract
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by fibrofatty replacement of the ventricular myocardium, a high risk of ventricular arrhythmias, and progressive ventricular dysfunction. The clinical course is highly variable, and optimal approaches to management remain undefined. ARVC is associated with pathogenic variants in genes encoding the cardiac desmosome. Genetic testing facilitates identification of at-risk family members, but penetrance of ARVC in pathogenic variant carriers is difficult to predict. Participation in endurance exercise is a known key risk factor. However, there remains significant uncertainty about which family member will develop disease and how best to approach longitudinal screening. Our clinically focused review describes how new insights gained from natural history studies, improved understanding of pathogenic mechanisms, and appreciation of genetic and environmental modifiers have set the stage for developing personalized approaches to managing both ARVC patients and their at-risk family members.
Keywords: arrhythmogenic right ventricular cardiomyopathy; desmosome; exercise; genetic testing; implantable cardioverter defibrillator; ventricular tachycardia.
Similar articles
-
Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update.Clin Res Cardiol. 2011 May;100(5):383-94. doi: 10.1007/s00392-011-0295-2. Epub 2011 Mar 1. Clin Res Cardiol. 2011. PMID: 21360243 Review.
-
Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy.Circulation. 2017 Nov 21;136(21):2068-2082. doi: 10.1161/CIRCULATIONAHA.117.030792. Circulation. 2017. PMID: 29158215 Free PMC article. Review.
-
Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis.Heart Rhythm. 2018 Jul;15(7):1097-1107. doi: 10.1016/j.hrthm.2018.01.031. Epub 2018 Feb 3. Heart Rhythm. 2018. PMID: 29408436
-
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D): Review of 16 Pediatric Cases and a Proposal of Modified Pediatric Criteria.Pediatr Cardiol. 2016 Apr;37(4):646-55. doi: 10.1007/s00246-015-1327-x. Epub 2016 Jan 8. Pediatr Cardiol. 2016. PMID: 26743400
-
Clinical diagnosis and management strategies in arrhythmogenic right ventricular cardiomyopathy.J Electrocardiol. 2000;33 Suppl:49-55. doi: 10.1054/jclc.2000.20323. J Electrocardiol. 2000. PMID: 11265736 Review.
Cited by
-
Crosstalk between coagulation and complement activation promotes cardiac dysfunction in arrhythmogenic right ventricular cardiomyopathy.Theranostics. 2021 Apr 3;11(12):5939-5954. doi: 10.7150/thno.58160. eCollection 2021. Theranostics. 2021. PMID: 33897891 Free PMC article.
-
Emerging Genotype-Phenotype Associations in Dilated Cardiomyopathy.Curr Cardiol Rep. 2022 Sep;24(9):1077-1084. doi: 10.1007/s11886-022-01727-z. Epub 2022 Jul 28. Curr Cardiol Rep. 2022. PMID: 35900642 Review.
-
Cardiomyopathy: pathogenesis and therapeutic interventions.MedComm (2020). 2024 Oct 25;5(11):e772. doi: 10.1002/mco2.772. eCollection 2024 Nov. MedComm (2020). 2024. PMID: 39465141 Free PMC article. Review.
-
Understanding Arrhythmogenic Cardiomyopathy: Advances through the Use of Human Pluripotent Stem Cell Models.Genes (Basel). 2023 Sep 25;14(10):1864. doi: 10.3390/genes14101864. Genes (Basel). 2023. PMID: 37895213 Free PMC article. Review.
-
Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually.ESC Heart Fail. 2021 Dec;8(6):4737-4750. doi: 10.1002/ehf2.13597. Epub 2021 Sep 8. ESC Heart Fail. 2021. PMID: 34498416 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical